Massachusetts’ Medicaid program relies on prices reported by pharmaceutical companies to determine what it will pay to pharmacies for ingredient costs for prescription drugs. Mylan has agreed to pay more than $2.6 million to settle the allegations it had reported inflated prices of its drugs. The settlement resolves claims related to drugs Mylan manufactured and sold from 1998-2003, including Clozapine, Phenytoin Sodium and Lorazapam.
In agreeing to the settlement, Mylan is not admitting any wrongdoing.
Read the news release about Mylan’s settlement with Massachusetts.
Read other coverage about pharmaceutical fraud:
– Advocacy Group: Pharmaceutical Companies Top List of DOJ Settlements
– Connecticut Wins $15M From Pharmaceutical Company McKesson in Drug Pricing Lawsuit
– Drug Maker Sandoz Settles Drug Pricing Allegations, Agrees to Pay $1.65M to Idaho
